• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

大手术中延长半衰期重组凝血因子IX——如何改善临床实践：个体内比较

Extended half-life rFIX in major surgery-How to improve clinical practice: An intraindividual comparison.

作者信息

Valeri Federica, Agnelli Giacchello Jacopo, Dainese Cristina, Valpreda Alessandra, Montaruli Barbara, Dosio Enrico, Boccadoro Mario, Borchiellini Alessandra

机构信息

Haematology Unit Regional Center for Hemorrhagic and Thrombotic Diseases City of Health and Science University Hospital of Molinette Turin Italy.

Regional Center for Hemorrhagic and Thrombotic Diseases Haematology Laboratory City of Health and Science University Hospital of Molinette Turin Italy.

出版信息

Clin Case Rep. 2020 Feb 12;8(3):531-534. doi: 10.1002/ccr3.2450. eCollection 2020 Mar.

DOI:10.1002/ccr3.2450
PMID:32185052
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7069879/
Abstract

Practical, safe, and effective hemostatic approach to orthopedic surgery using Extended Half-Life factor IX in hemophilia B. By intraindividual comparison, we found a lower FIX consumption, number of infusions, and cost compared to plasma-derived FIX.

摘要

在乙型血友病中使用延长半衰期的凝血因子IX进行骨科手术的实用、安全且有效的止血方法。通过个体内比较，我们发现与血浆源性凝血因子IX相比，凝血因子IX的消耗量、输注次数和成本更低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abc/7069879/1c44d3343a8a/CCR3-8-531-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abc/7069879/ee52d4e44288/CCR3-8-531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abc/7069879/1c44d3343a8a/CCR3-8-531-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abc/7069879/ee52d4e44288/CCR3-8-531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abc/7069879/1c44d3343a8a/CCR3-8-531-g002.jpg

相似文献

1
Extended half-life rFIX in major surgery-How to improve clinical practice: An intraindividual comparison.大手术中延长半衰期重组凝血因子IX——如何改善临床实践：个体内比较
Clin Case Rep. 2020 Feb 12;8(3):531-534. doi: 10.1002/ccr3.2450. eCollection 2020 Mar.
2
In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.三种延长半衰期因子 IX 浓缩物的药代动力学特性的计算机比较。
Eur J Clin Pharmacol. 2021 Aug;77(8):1193-1200. doi: 10.1007/s00228-021-03111-2. Epub 2021 Feb 24.
3
Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice.血友病 B 小鼠体内重组凝血因子 IX、延长半衰期重组凝血因子 IX Fc 融合蛋白和糖基化聚乙二醇化重组凝血因子 IX 的生物分布。
Blood Coagul Fibrinolysis. 2023 Sep 1;34(6):353-363. doi: 10.1097/MBC.0000000000001230. Epub 2023 Jul 17.
4
Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.重组人凝血因子IX：犬血友病B的替代疗法、预防措施及药代动力学
Blood. 1996 Oct 1;88(7):2603-10.
5
Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX.因子 IX 与因子 XIII-B 亚基融合可改善因子 IX 的药代动力学特征。
Thromb Haemost. 2018 Dec;118(12):2053-2063. doi: 10.1055/s-0038-1675787. Epub 2018 Nov 19.
6
Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.血浆源性与重组因子 IX 在乙型血友病患者中的药代动力学和药效学特性：一项前瞻性交叉研究。
J Thromb Haemost. 2014 Dec;12(12):2044-8. doi: 10.1111/jth.12756. Epub 2014 Nov 11.
7
Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.重组因子IX Fc融合蛋白维持完整的促凝血特性，并在血友病B小鼠中展现出延长的疗效。
PLoS One. 2016 Feb 3;11(2):e0148255. doi: 10.1371/journal.pone.0148255. eCollection 2016.
8
In vivo intranasal delivery of coagulation factor IX: a proof-of-concept study.凝血因子IX的体内鼻腔给药：一项概念验证研究。
J Thromb Haemost. 2023 Nov;21(11):3117-3123. doi: 10.1016/j.jtha.2023.08.019. Epub 2023 Aug 25.
9
Characterization of a recombinant factor IX molecule fused to coagulation factor XIII-B subunit.与凝血因子 XIII-B 亚基融合的重组因子 IX 分子的特性分析。
Haemophilia. 2023 Nov;29(6):1483-1489. doi: 10.1111/hae.14855. Epub 2023 Sep 14.
10
Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain.在西班牙，首次转换为长效因子 IX（阿柏西普，rFIX-FP）的临床、药代动力学和经济分析。
BMJ Case Rep. 2020 Oct 13;13(10):e234142. doi: 10.1136/bcr-2019-234142.

引用本文的文献

1
Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis.重组FIX Fc用于B型血友病的大手术：FIX血浆活性水平与有效止血
Res Pract Thromb Haemost. 2023 Aug 7;7(6):102169. doi: 10.1016/j.rpth.2023.102169. eCollection 2023 Aug.
2
Managing Relevant Clinical Conditions of Hemophilia A/B Patients.管理甲型/乙型血友病患者的相关临床病症。
Hematol Rep. 2023 Jun 7;15(2):384-397. doi: 10.3390/hematolrep15020039.
3
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies.

本文引用的文献

1
Hip arthroplasty in haemophilia: a systematic review.血友病患者的髋关节置换术：一项系统评价
Hip Int. 2018 Sep;28(5):459-467. doi: 10.1177/1120700018793777. Epub 2018 Aug 20.
2
Perioperative replacement therapy in haemophilia B: An appeal to "B" more precise.乙型血友病围手术期替代治疗：呼吁更精准的“B”。
Haemophilia. 2018 Jul;24(4):611-618. doi: 10.1111/hae.13469. Epub 2018 Apr 29.
3
Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
使用重组凝血因子VIII Fc和凝血因子IX Fc管理血友病患者的手术：3期关键研究的安全性和有效性数据。
Res Pract Thromb Haemost. 2022 Jul 26;6(5):e12760. doi: 10.1002/rth2.12760. eCollection 2022 Jul.
4
Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management.重度乙型血友病患者的神经外科手术：使用阿伐凝血因子α进行围手术期管理的经验
Clin Case Rep. 2022 May 23;10(5):e05848. doi: 10.1002/ccr3.5848. eCollection 2022 May.
真实世界中血友病 B 患者接受标准半衰期和延长半衰期产品以及从标准半衰期产品转换为延长半衰期产品的凝血因子 IX 用量和相应支出的分析。
J Manag Care Spec Pharm. 2018 Jul;24(7):643-653. doi: 10.18553/jmcp.2018.17212. Epub 2018 Jan 24.
4
Total Hip Arthroplasty in Hemophilia Patients: A Mid-term to Long-term Follow-up.血友病患者的全髋关节置换术：中期至长期随访
Orthop Surg. 2017 Nov;9(4):359-364. doi: 10.1111/os.12354.
5
Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.新型延长半衰期FVIII/IX浓缩物的临床试验结果
J Clin Med. 2017 Mar 28;6(4):39. doi: 10.3390/jcm6040039.
6
The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.在常规临床实践中使用延长半衰期的凝血因子浓缩物：英国血液学标准委员会的指南
Haemophilia. 2016 Jul;22(4):487-98. doi: 10.1111/hae.13013. Epub 2016 Jun 16.
7
Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.长效重组因子IX Fc融合蛋白（rFIXFc）用于3期B-LONG研究中B型血友病患者的围手术期管理。
Br J Haematol. 2015 Jan;168(1):124-34. doi: 10.1111/bjh.13112. Epub 2014 Sep 11.
8
Guidelines for the management of hemophilia.血友病管理指南。
Haemophilia. 2013 Jan;19(1):e1-47. doi: 10.1111/j.1365-2516.2012.02909.x. Epub 2012 Jul 6.
9
Clinical outcomes and patient satisfaction following total joint replacement in haemophilia--23-year experience in knees, hips and elbows.血友病患者全关节置换术后的临床结果和患者满意度：膝关节、髋关节和肘关节 23 年的经验。
Haemophilia. 2012 Jan;18(1):86-93. doi: 10.1111/j.1365-2516.2011.02579.x. Epub 2011 Jun 7.
10
Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis.血浆源性凝血因子 IX 浓缩物（AlphaNine® SD）在接受手术干预的乙型血友病患者中的安全性和疗效：单机构回顾性分析。
Haemophilia. 2011 Jan;17(1):e196-201. doi: 10.1111/j.1365-2516.2010.02354.x.